November 12, 2021 7:43am

End this week, as a weak aftermarket again defies expectation

Pre-open indications: 2 SELLs, 6 BUYs and 1 Pump (or No Promote)

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.28% (+101 points), S&P futures are UP +0.20% (+10 points) and NASDAQ futures are UP +0.25% (+40 points)

 

Stock futures are a tad higher early Friday morning,

European stocks were basically flat,

Asia-Pacific stocks were up following our indexes.

 

Henry’omics:

The market appears to have withstood Wednesday’s hottest inflation report in 30 years. The major indexes are on track to snap five-week winning streaks but are still within striking distance of their recent records.

 

Note: Johnson & Johnson (JNJ) saw its shares pop +$4.44 or +4% to $169.50) in pre-market trading following a (Wall Street Journal) report that the company is splitting in two. The move will entail breaking off its consumer health division into a separate publicly traded company. One will include prescription drugs and medical devices, while the other will concentrate on consumer products, such as Band-Aid bandages and baby powder.

 

Economic Data Docket: The preliminary read for November consumer sentiment and the September report on job openings and labor turnover will be released on Friday morning.

 

If you didn’t remember what happen at Thursday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Thursday’s evening’s recap: “from an extreme downside to a barely downslide. The push/pull didn’t quite work with half the market closed (the bond market) for Veterans Day)” … https://www.regmedinvestors.com/articles/12180

Q4: November, 3 positive and 6 negative close to date

  • October, 8 positive and 13 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining SELL with a Pump or No Promote:

Biostage (BSTG) closed down -$0.22 to $2.60 with 2,005 shares traded after Wednesday’s +$0.18 with 2,006 shares traded after Tuesday’s -$0.03 with 3,304 shares traded, Monday’s +$0.07 with 7,082 shares traded after being down -$0.60, Friday’s flat again at $2.60 with 9,003 shares traded and last Thursday’s flat with 82 shares traded, the previous Wednesday’s -$0.40 to $2.60 with 1,208 shares traded, Tuesday’s -$0.10 to $3.00 with 200 shares traded following Monday’s flat again with 80 shares traded.

  • What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.

 

Probabilities versus aftermarket/pre-open share pricing indication moves:

Maintaining SELL into Strength:

Chinook Therapeutics (KDNY) closed up +$0.10 to $16.08 after Wednesday’s +$1.47 to $15.98 after Tuesday’s +$0.32 to $14.51 and Monday’s -$1.77 with NO pre-market indication after executing an up-sized offering. Watch for the flipping post offering …

 

BUY from SELL:

BioLife Solutions (BLFS) closed down AGAIN -$0.81 TO $48.80 after Wednesday’s -$3.90 to $49.61, Tuesday’s +$0.28 to $53.51, Monday’s -$0.59 and last Friday’s -$4.73 with a positive +$0.25 or +0.51% pre-market indication.

 

SELL:

Verastem (VSTM) closed up +$0.28 to $2.93 and has a negative -$0.02 or -0.68% pre-market indication.

 

Maintaining BUY:

Editas Medicine (EDIT) closed up +$0.31 to $38.20 after Wednesday’s -$2.67 to $37.89, Tuesday’s -$0.01 to $40.56, Monday’s +$3.07 to $40.57 and last Friday’s -$0.34 with a positive pre-market of +$0.20 or +0.52%.

 

BUY:

CRISPR Therapeutics (CRSP) closed up +$0.34 to $87.92 with a positive +$1.90 or +2.16% aftermarket indication.

Homology Medicine (FIXX) closed down -$0.13 to $5.87 with a positive +$0.33 or +5.62% aftermarket indication.

Intellia Therapeutics (NTLA) closed up +$3.72 to $130.50 after Wednesday’s -$11.58 to $126.78, Tuesday’s +$2.29 to $138.36, Monday’s +$0.59 to $136.07 and last Friday’s+$1.54 with a positive +$2.50 or +1.92% pre-open indication.

Global Blood Therapeutics (GBT) closed down again -$0.65 to $31.94 after Wednesday’s -$0.87 to $32.59, Tuesday’s $33.46 and Monday’s $35.40 with a positive +$0.05 or +0.16% pre-market indication.

 

The BOTTOM LINE: Beware jumping into a buying of sector stocks that look like bargains!

As I keep asking, “is there a bounce after a trounce and how many?”

I am still manning the bully pulpit, expressing the theme of “Reducing exposure as well as being patient in your willingness to stay fully invested, I’d been recommending very careful buy-ins for the hopes of gains through the month and year-end.

We are seeing to date, two (2) net income – Bellicum Pharmaceuticals (BLCM) and BioLife Solutions (BLFS)

  • Twenty-one (21) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood Therapeutics (GBT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO),  Cellectis SA (CLLS), Editas Medicine (EDIT) and today’s … Applied Genetic Technologies (AGTC) and Vericel (VCEL)>

… Earning’s releases that initiated Q3 earnings reporting season and beginning the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

The stem, cell and gene therapy earnings continue with Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date with more coming).

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.